I'm LongbridgeAI, I can summarize articles.The Week
Manulife Financial (MFC) closed the week down 3.11% at $43.24, lagging the S&P 500’s 2.68% decline by about 0.43 percentage points. The week’s range was 7.48%, with a rise-then-pullback pattern: Monday through Wednesday the stock climbed from $44.65 to finish Wednesday at $45.99, Thursday saw an intraday high of $46.19 before a sharp reversal, and Friday dipped to $42.85 intraday, closing at $43.24. Average daily volume of about 1.94m shares ran roughly 29.7% above the 60-day median.
Key Events
The company’s own news centred on Thursday’s third-quarter results and investor day. Core EPS rose 6% year over year to CAD 1.24, headline earnings reached CAD 2.1b, up 4%, with Asia and North American insurance operations providing strength; Hong Kong and Macau headline earnings grew 19% year over year. Management presented an investor strategy targeting core ROE of 18% or above by 2027, and declared a quarterly dividend of CAD 0.485 per share, payable on December 21. The stock hit a 52-week high in after-hours trading following the release, then reversed lower, and fell more than 2% in Friday’s regular session. Separately, on Friday Manulife warned shareholders against accepting an Ocehan LLC offer to buy up to 100,000 shares below market price.
Analyst Ratings
Fifteen firms cover Manulife: 6 rate it buy, 3 overweight, 4 hold, and 2 underweight, with no sell or no-opinion ratings. The consensus recommendation is buy, with a consensus target of $35.38, about 18.2% below the latest spot of $43.24. The high and low target prices are both $35.38, indicating little dispersion. Within its industry group of 21 covered names, Manulife ranks 4th.
The Week Ahead
On Tuesday, November 10, the US releases CPI and core CPI. Market expectations put headline CPI at 3.9% year over year and 0.3% month over month, with core CPI at 2.8% year over year and 0.2% month over month. On the company side, fiscal 2026 annual results are scheduled for February 10, 2027 after the close, with consensus estimates at EPS of $2.83 and revenue of $37.1b. The 2027 core ROE target laid out this week will keep execution and the quality of divisional growth under scrutiny beyond the next earnings print.
In Short
This week split into two tracks: earnings and strategy defined the fundamental story, with Asia and North America supporting profit growth, while the stock reversed after the post-earnings 52-week high and closed down, lagging the broader market. The latest session’s flow data showed small and medium orders as net buyers and large orders with no net selling. Analyst consensus is buy, yet the consensus target sits 18.2% below spot, adding friction to the near-term setup. The next reads come from CPI and how insurers trade around rates, plus Manulife’s progress toward its 2027 return target.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
